<DOC>
	<DOCNO>NCT02580994</DOCNO>
	<brief_summary>This multicenter , open-label , two arm , control , randomize phase II trial investigate activity pembrolizumab ( MK-3475 ) combination standard chemotherapy Extensive Disease ( ED ) -SCLC .</brief_summary>
	<brief_title>Pembrolizumab Untreated Extensive SCLC</brief_title>
	<detailed_description>This multicenter , open-label , two arm , control , randomize phase II trial investigate activity pembrolizumab ( MK-3475 ) combination standard chemotherapy ED-SCLC . Extended stage Small Cell Lung Cancer ( SCLC ) patient register , sign informed consent , centrally randomize 1:1 experimental arm ( Arm A ) control arm ( Arm B ) . Cross-over time disease progression allow arm B .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically confirm SCLC Extended disease accord criterion Veteran 's Administration Lung Cancer Group ( VALG ) No prior systemic therapy SCLC Measurable disease Previous palliative brain radiotherapy allow terminate least 3 week treatment start Partial complete response accord RECIST ( Response Evaluation Criteria Solid Tumors ) 1.1 2 cycle platinumbased induction chemotherapy regimen Performance Status 34 No adequate organ function Less 3 month life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>phase II</keyword>
	<keyword>randomize</keyword>
	<keyword>pembrolizumab</keyword>
</DOC>